Id: acc0307
Group: 1sens
Protein: p70S6K
Gene Symbol: RPS6KB1
Protein Id: P23443
Protein Name: KS6B1_HUMAN
PTM: phosphorylation
Site: Thr389
Site Sequence: SQFDSKFTRQTPVDSPDDSTL
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: LUAD
Disease Cellline: PC9
Disease Info:
Drug: erlotinib
Drug Info: "Erlotinib is a medication used in the treatment of certain types of lung cancer, particularly non-small cell lung cancer (NSCLC), and pancreatic cancer, often as a maintenance therapy or after chemotherapy failure."
Effect: inhibit
Effect Info: "BEZ235 inhibits the phosphorylation of Akt, p70S6K, and S6RP, thereby suppressing the growth of erlotinib-resistant tumors induced by HGF."
Note:
Score: 5.0
Pubmed(PMID): 23319394
Sentence Index:
Sentence:

Sequence & Structure:

MRRRRRRDGFYPAPDFRDREAEDMAGVFDIDLDQPEDAGSEDELEEGGQLNESMDHGGVGPYELGMEHCEKFEISETSVNRGPEKIRPECFELLRVLGKGGYGKVFQVRKVTGANTGKIFAMKVLKKAMIVRNAKDTAHTKAERNILEEVKHPFIVDLIYAFQTGGKLYLILEYLSGGELFMQLEREGIFMEDTACFYLAEISMALGHLHQKGIIYRDLKPENIMLNHQGHVKLTDFGLCKESIHDGTVTHTFCGTIEYMAPEILMRSGHNRAVDWWSLGALMYDMLTGAPPFTGENRKKTIDKILKCKLNLPPYLTQEARDLLKKLLKRNAASRLGAGPGDAGEVQAHPFFRHINWEELLARKVEPPFKPLLQSEEDVSQFDSKFTRQTPVDSPDDSTLSESANQVFLGFTYVAPSVLESVKEKFSFEPKIRSPRRFIGSPRTPVSPVKFSPGDFWGRGASASTANPQTPVEYPMETSGIEQMDVTMSGEASAPLPIRQPNSGPYKKQAFPMISKRPEHLRMNL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
RPS6KB1 TAS0612 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Recruiting neoplasm ClinicalTrials
RPS6KB1 MSC-2363318A Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed neoplasm ClinicalTrials
RPS6KB1 LY-2780301 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed lymphoma ClinicalTrials
RPS6KB1 XL-418 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Suspended neoplasm ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated renal cell carcinoma ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated non-small cell lung carcinoma ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated metastasis ClinicalTrials
RPS6KB1 LY-2780301 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Completed metastasis ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated neuroendocrine neoplasm ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Completed cancer ClinicalTrials
RPS6KB1 LY-2584702 Ribosomal protein S6 kinase 1 inhibitor 1 Terminated cancer ClinicalTrials
RPS6KB1 XL-418 Ribosomal protein S6 kinase (P70S6K) inhibitor 1 Suspended cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
RPS6KB1-Thr389
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
T 389 P Liver cancer Phosphorylation 23537100

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: